NYSE: CORCencora

    Cencora Q4 FY2026 Results: Net Income $519 Million on Revenue of $88.35 Billion

    • US stocks
    • Earnings
    • Health Care
    An open hand holding several tablets and capsules in red, green, white and brown against a green background
    guvo59, via Wikimedia Commons (CC0). Illustrative image.

    Cencora (NYSE: COR) reported fiscal 2026 fourth quarter results for the three months to 30 Sep 2026, with GAAP revenue of $88.4 billion and GAAP net income attributable to the company of $519.4 million, it said on 4 Nov 2026. GAAP diluted EPS was $2.71; adjusted diluted EPS, a company-defined non-GAAP measure, was $4.66.

    Key highlights

    • Operating income (GAAP): $906.8 million, against $18.5 million a year earlier
    • Operating margin (GAAP): 1.03%, up 1.01 percentage points YoY
    • Adjusted operating income (company-defined, non-GAAP): $1.2 billion, up 22.1% YoY
    • Quarterly dividend: $0.66 per share, up 10% from $0.60
    • Fiscal 2027 adjusted diluted EPS outlook (company-defined, non-GAAP): $19.40 to $19.75

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ4 FY2026Q4 FY2025YoYQ3 FY2026QoQ
    Revenue88,354.583,728.6+5.5%84,754.8+4.2%
    906.818.5+4800.9%1,120.2-19.1%
    519.4-339.7n/a763.5-32.0%
    Diluted EPS ($)2.71-1.75n/a3.94-31.2%

    Figures are in $ million except EPS; YoY compares with Q4 FY2025 and QoQ with Q3 FY2026. Q4 FY2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    Against the same quarter a year earlier, revenue rose 5.5% and GAAP operating income rose from $18.5 million to $906.8 million. Against the third quarter of fiscal 2026, revenue rose 4.2%, while operating income fell 19.1% from $1,120.2 million and diluted EPS fell 31.2% from $3.94. The GAAP operating margin of 1.03% was up 1.01 percentage points from a year earlier and down 0.29 percentage points from the third quarter.

    Adjusted figures exclude items the company names

    Adjusted diluted EPS is a company-defined non-GAAP measure that excludes items such as gains from antitrust litigation settlements, LIFO credits, acquisition-related intangibles amortization, deal and integration expenses, restructuring, and discrete tax items. The company says it excludes these as not indicative of its ongoing operating performance. On that adjusted basis the operating margin was 1.41%, against 1.22% a year earlier, and the adjusted effective tax rate was 20.2%, against 20.6% a year earlier.

    Operating income rose in all three segments

    U.S. Healthcare Solutions revenue was $78.3 billion, up 5.4%, and its operating income was $997.6 million, up 22.0%. The company attributes that gain to higher gross profit, including from increased pharmaceutical sales and the OneOncology acquisition. International Healthcare Solutions operating income was $152.1 million, up 16.4%, which the company attributes mainly to its Canadian and global specialty logistics businesses.

    Fiscal 2027 outlook and deals

    For fiscal 2027 the company expects adjusted diluted EPS of $19.40 to $19.75, against $17.97 in fiscal 2026 on the same basis. It does not give GAAP expectations, saying certain financial information cannot be reasonably estimated. The company has entered a definitive deal to acquire American Oncology Network, a physician-led group of more than 350 oncology providers across 21 states, and has signed to sell its Profarma stake, with that sale expected to close in the first quarter of fiscal 2027.

    Inference

    The diluted share count was 191.7 million, 1.1% lower than a year earlier, which the company attributes to share repurchases. The company declared a quarterly dividend of $0.66 per share on 3 Nov 2026, payable 30 Nov 2026 to holders of record at the close of business on 13 Nov 2026.

    The release does not state the quarter's share repurchase amount or its operating cash flow. The next dated step in the release is the dividend payment on 30 Nov 2026.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts